Quince Therapeutics, Inc. (NASDAQ:QNCX) Stock Rated “Moderate Buy” by Sell-Side Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has been assigned a consensus rating of “Moderate Buy” from the fourteen brokerages that are covering the stock, MarketBeat Ratings reports. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among brokers that have covered the stock in the last year is $189.88.

Several equities research analysts have issued reports on the company. Citigroup restated a “market outperform” rating on shares of Quince Therapeutics in a research report on Tuesday, September 29th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $70.00 price target on shares of Quince Therapeutics in a research report on Tuesday, August 18th. Weiss Ratings upgraded Quince Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, September 29th. Oppenheimer began coverage on Quince Therapeutics in a research note on Wednesday, July 29th. They set an “outperform” rating and a $82.00 price objective on the stock. Finally, Citizens Jmp raised Quince Therapeutics from a “market perform” rating to an “outperform” rating and set a $77.00 price objective on the stock in a report on Tuesday, September 22nd.

Institutional Investors Weigh In On Quince Therapeutics

A hedge fund recently bought a new stake in Quince Therapeutics stock. BlackRock Inc. bought a new position in Quince Therapeutics, Inc. (NASDAQ:QNCX) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,702 shares of the company’s stock, valued at approximately $31,000. BlackRock Inc. owned about 0.17% of Quince Therapeutics as of its most recent SEC filing. 30.75% of the stock is currently owned by institutional investors and hedge funds.

Quince Therapeutics Stock Up 0.9%

NASDAQ QNCX opened at $32.01 on Wednesday. The firm has a market cap of $32.65 million, a P/E ratio of -0.20 and a beta of 1.33. The company’s 50 day moving average is $30.80 and its 200-day moving average is $24.88. Quince Therapeutics has a 12-month low of $15.10 and a 12-month high of $909.98.

Quince Therapeutics (NASDAQ:QNCX) last released its quarterly earnings data on Friday, August 14th. The company reported ($12.31) EPS for the quarter, topping the consensus estimate of ($28.02) by $15.71. Equities analysts expect that Quince Therapeutics will post -8.39 EPS for the current year.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc (NASDAQ:QNCX) is a clinical-stage biotechnology company developing therapies for rare and debilitating diseases. The company focuses on precision medicines designed to address underlying disease mechanisms and unmet medical needs in patient populations that may have limited treatment options.

Quince’s pipeline includes efzofitimod, an investigational immunomodulator being developed for pulmonary sarcoidosis, a rare inflammatory disease that can affect lung function.